hsa-mir-500a: Hsa-mir-500a is a pre-miRNA that encodes a microRNA. It is annotated to have its major arm as the 5p arm [PMC3303722]. Hsa-mir-500a has been found to be negatively associated with poor overall survival in pancreatic adenocarcinoma [PMC9158148]. It has also been identified as differentially expressed in painful and non-painful human lingual nerve neuromas, with reduced levels associated with the presence of pain [PMC6620726]. Hsa-mir-500a has been predicted to target genes involved in potassium channels, such as Kcna1 and Kcnj1 [PMC6620726]. Additionally, it has been associated with axon regeneration following injury and may contribute to the regulation of several potassium channels [PMC6620726]. Hsa-mir-500a has also been found to be differentially expressed in hepatocellular carcinoma and neuroblastoma, where its upregulation is associated with poor response to chemotherapy [PMC3521178] [PMC5609578]. Furthermore, it has been identified as one of the miRNAs that could predict gene expression regulation in prostate cancer [PMC8426106]. The inhibitory effect of hsa-mir-500a on gene expression was found to be stronger for the T allele compared to the C allele in HepG2 cells [PMC9692299]. Additionally, hsa-mir-500a was found to be differentially expressed between Black/AA and White/EA patients with triple-negative breast cancer and correlated with AR expression levels [PMC9497140].